Mechanism for Exercise to Delay Cardiac Aging

September 7, 2023 updated by: Xiao-dong Zhuang

The αKlotho Protein-mediated NLRP3/Caspase-1/GSDMD Pathway Counteracts Myocardial Stunning: a Novel Mechanism for Exercise to Delay Cardiac Aging

The goal of this clinicaltrial is to assess and compare isokinetic performance, surface electromyography, laboratory parameters, and cardiorespiratory function both before and after engaging in vigorous intermittent lifestyle physical activity(VILPA) within a healthy population.

The main question it aims to answer is:

[1] Does VILPA yield effective outcomes?

Throughout the course of the trial, participants will engage in a simulated regimen of vigorous intermittent lifestyle physical activity for a duration of 8 weeks. The efficacy of the exercise protocol will be quantified and evaluated through the utilization of a wearable device.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 510006
        • Guangdong Pharmaceutical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

University students

Description

Inclusion Criteria:

  1. Healthy Adults
  2. No exercise habits (more than 3 months)

Exclusion Criteria:

  1. Exercising ≥ 3 times per week;
  2. the presence of chronic diseases, such as hypertension, hyperglycemic states, etc;
  3. have conducted an exercise program in the past three months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
intervention group
The intervention measures encompass the implementation of simulated vigorous intermittent lifestyle physical activity for all participants. The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.
Other: Vigorous intermittent lifestyle physical activity
The specific exercise regimen involves performing rope jumping activities three times a day, with each session aimed at surpassing the exercise threshold (not conducted in a continuous manner), where the heart rate should exceed 160 beats per minute. This routine will be undertaken five times a week, continuously for a span of 8 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Isometric Strength Test
Time Frame: 15 minutes
Isokinetic muscle strength testing with the Isomed 2000
15 minutes
Surface electromyography
Time Frame: 30 minutes
30 minutes
Exercise Flat Test
Time Frame: 30 minutes
cardiopulmonary function
30 minutes

Secondary Outcome Measures

Outcome Measure
Time Frame
Fasting glucose
Time Frame: 5 minutes
5 minutes
Blood lipid
Time Frame: 5 minutes
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xiao-dong Zhuang

Investigators

  • Study Director: Lizhen Liao, PhD, Department of Health, Guangdong Pharmaceutical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 12, 2023

Primary Completion (Actual)

July 10, 2023

Study Completion (Actual)

September 1, 2023

Study Registration Dates

First Submitted

August 31, 2023

First Submitted That Met QC Criteria

September 7, 2023

First Posted (Actual)

September 11, 2023

Study Record Updates

Last Update Posted (Actual)

September 11, 2023

Last Update Submitted That Met QC Criteria

September 7, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • K0001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe